Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 27;24(5):411. doi: 10.3892/ol.2022.13531

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Response of the mini-PDX to various chemotherapy regimens and the change of body weight during drug delivery. (A) The proliferation of tumor cells in mini-PDX implants was observed in mice treated with vehicle, Doc + S-1, Cape + Oxa and Irino + S-1. The drug treatment began 1 day after tumor cell implantation. The tumor cell proliferation rate relative to that of the control group was calculated after the 7-day treatment. **P<0.001 vs. the vehicle group. (B) The change in body weight of the mice was monitored. Throughout the experiment, no significant reduction in the weight of mice in each group was detected, suggesting that the dosage of the drug regimen was within the safe range. T, tumor; C, control; Doc, docetaxel; Cape, capecitabine; Oxa, oxaliplatin; Irino, irinotecan; S-1, tegafur-gimeracil-oteracil (tegio); RCBW, relative change in body weight.